
    
      This is an Open label, randomized, active control, parallel-group pilot trial to examine the
      effect of initiation of APIXABAN at days 0-3 (TIA), days 3-5 (small stroke) and days 7-9
      (medium stroke) to decrease fatal and/or recurrent stroke/TIA in 120 subjects who have
      suffered a recent( 0 to 48 hours from symptoms) TIA, or small to medium ischemic stroke
      compared to standard of care warfarin treatment regimen. Subjects will be randomly assigned
      in a 1:1 ratio to one of two treatment arms (apixaban or warfarin). Subjects will be followed
      for a total of 180 days during from screening through monthly follow-up visits.
    
  